Benign Prostatic Hyperplasia Treatment Market Excessive Growth Opportunities, Trends, Size And Share

(MENAFN- America News Hour) Benign Prostatic Hyperplasia Treatment Market report delivers detailed overview of the benign prostatic hyperplasia treatment market in terms of market segmentation by treatment type, application, and region. Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

Benign Prostatic Hyperplasia Treatment Market Statistics –

  • USD 7 billion revenue in 2022
  • The market size is projected to record a valuation of over USD 13 billion by 2035
  • The membrane filtration industry is slated to observe 6% growth rate through 2023-2035

Get Your Free Sample Copy of this Report @

The benign prostatic hyperplasia treatment market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029 on account of the increasing elderly population and subsequent rise in prevalence of benign prostatic hyperplasia. Additionally, the rapid rise in preference for minimal invasive surgeries for the treatment of benign prostatic hyperplasiais also likely to bolster the growth of this market.
As per National Center for Biotechnology Information, clinical benign prostate hyperplasia is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms. The prevalence of benign prostate hyperplasia increases after the age of 40 years, with a prevalence of 8%-60% at age 90 years. The market is segmented by treatment type into drug and surgery. Among these segments, the drug segment is anticipated to hold the largest share by the end of 2021 in the benign prostatic hyperplasia treatment market due to its use as a first line of treatment among men with moderate symptoms. Surgery segment is also projected to witness growth due to greater adoption of minimally invasive surgeries by patients with severe symptoms.

According to recent study by Research Nester, the Benign Prostatic Hyperplasia Treatment Market size is anticipated to surpass USD 13 Bn by 2035 and is projected to expand at CAGR of over 6% from 2023 to 2035.

Major players include in the global Benign Prostatic Hyperplasia Treatment Market:

  • Pfizer Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Cardinal Health Inc.
  • NxThera, Inc.
  • Veru, Inc.
  • Teleflex Incorporated
  • Eli Lily & Company
  • Sanofi S.A.
  • GSK plc
  • Mylan N.V.
  • AbbVie Inc.

Get Your Free Sample Copy of this Report @

Rising prevalence of Benign Prostatic Hyperplasia Due to Increase in Geriatric Population and Increasing preference for Minimally Invasive Surgeries to Drive Market Growth

According to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population. Along with this, the number of persons above 80 years or older is also projected to triple by the end of 2050.

Age is one of the most predominant risk factors for benign prostatic hyperplasia. It has been observed that men whose age is above 40 years or more possess a greater risk of having benign prostatic hyperplasia. As a consequence, the rising prevalence of benign prostatic hyperplasia in recent years is expected to boost the market growth in upcoming years.

However, the limited outreach of drug treatment in terms of patients and expensive cost of surgery are some of the factors that are estimated to restrain market growth in the near future.

This report also provides the existing competitive scenario of some of the key players of the benign prostatic hyperplasia treatment market which includes company profiling of Boston Scientific Corporation (NYSE: BSX), Olympus Corporation (TYO), Abbott (NYSE: ABT), Coloplast Group (CPH), GlaxoSmithKline PLC (LON: GSK), Merck & Co. (NYSE: MRK), Eli Lilly (NYSE: LLY), Asahi Kasei Corporation (TYO), and Astellas Pharma Inc. (TYO). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the benign prostatic hyperplasia treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Buy a Copy of this Strategic Report to drive your Business Growth

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

Contact for more Info:

AJ Daniel


U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919


America News Hour

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.